IL6R and COVID-19: Hwang et al. (2022) offered the most conclusive evidence that tocilizumab medication helps hospitalized COVID-19 patients. In addition, tocilizumab and sarilumab, in combination with corticosteroids, are recommended by the WHO to treat severe COVID-19. According to the study (NCT04322188), patients with rapidly developing COVID-19 respiratory pneumonia who require supplemental oxygen may benefit from siltuximab (IL-6R monoclonal antibody) therapy due to lower death and chemokines hyper-inflammation in Figure 5.